Overview

Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.
Phase:
N/A
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborator:
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Treatments:
Niacinamide
Sorafenib